Moreover, glucagon-like peptide-1 receptor agonists (GLP1-RA) have demonstrated significant benefits in patients with high cardiovascular risk, excess body weight or obesity and HF, in particular HFpEF. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.